Covaxin: GB18 Injection Receives Approval for Clinical Trials by the US FDA

Kexing Pharmaceuticals announced that its wholly-owned subsidiary, Shenzhen Kexing, has received approval from the US FDA for clinical trial application of the innovative drug GB18 injection. The drug can now be used in clinical trials in the United States, with indications for treating cancer cachexia. GB18 injection is a novel drug targeting the GDF15 receptor, used for treating cancer cachexia. The molecule incorporates a unique Fc fusion nanobody structure design, which improves the drug's stability and bioavailability, and significantly enhances its performance in inhibiting signal pathway transmission.